![\"Official](\"https:\/\/rtmedical.com.br\/wp-content\/uploads\/2026\/05\/siemens-healthineers-andreas-schneck-imagem.jpg\")
The most visible move is the departure of Andr\u00e9 Hartung, a 25-year company veteran who ran the diagnostic imaging division through a period of meaningful expansion: market share gains, the launch of photon-counting CT (Naeotom Alpha) and the development of dry-cool MR systems that reduce dependence on liquid helium. He is replaced by Andreas Schneck, an executive with cross-cutting experience in diagnostic and interventional imaging, including running MR operations in Shenzhen between 2020 and 2023 and subsequently overseeing the global MR segment.<\/p>\n
What changes inside diagnostic imaging<\/h2>\n
The division under Schneck covers CT, MR, X-ray, mammography and ultrasound \u2014 likely the group’s largest revenue engine. Picking a leader with deep MR background and direct exposure to the Chinese market signals two strategic priorities. First, sustaining the pace of MR innovation: Siemens has been expanding its catalog of magnets with reduced cooling, with operationally relevant implications for hospitals worldwide where helium logistics is costly. Second, sustaining the competitive race against Philips and GE on premium equipment and tightening integration with AI platforms. To frame the backdrop, see the consolidation GE HealthCare just pushed through in its own imaging division in 2026<\/a> \u2014 a move now mirrored at Siemens.<\/p>\n There is also the geographic execution layer. Three years running MR operations in China gives Schneck a useful playbook for navigating distinct regulatory cycles, local sourcing and pricing dynamics in emerging markets. That can speed up product adaptation for markets such as Brazil and Mexico, where total cost of ownership weighs heavily in purchasing decisions.<\/p>\n In parallel, Philipp Fischer takes over the Advanced Therapies division, succeeding Carsten Bertram. Bertram remains in an advisory capacity until his planned retirement in 2027, supporting chief technology officer Martin Stumpe and serving as senior advisor to the managing board. Fischer is a trained physician who joined Siemens in 2009 and has held leadership roles in cardiovascular imaging and CT \u2014 a relevant combination for a division spanning angiography, hybrid suites and robotic intervention platforms. The expected focus is tighter integration of interventional imaging with oncology and cardiology workflows, in line with the rising trend of theranostics-ready suites.<\/p>\n In the Europe, Middle East and Africa (EMEA) region, Sonja Wehsely replaces Bernd Ohnesorge, who is stepping down after eight years for personal reasons and remains as senior advisor focused on strategy and key customer relationships. Wehsely joined Siemens in 2017 from the Austrian public sector and currently runs a multi-country region covering Central and Eastern Europe and Central Asia \u2014 meaning she knows mid-complexity regulatory markets, a sensitive area in a region marked by public procurement and budget variability.<\/p>\n On human resources, Elaine Becraft becomes chief human resources officer on October 1, reporting to Darleen Caron, who takes on broader scope including labor relations and regional oversight. Becraft today leads HR for the diagnostics segment and has prior senior HR experience in Europe and the United States.<\/p>\n For hospitals and clinics running Siemens fleets \u2014 in MR, CT, angiography or ultrasound \u2014 four practical points deserve attention. First, the product roadmap should not break, since all promoted leaders come from within and know the portfolio inside out. Second, it is reasonable to expect more emphasis on lower-TCO offerings for emerging markets, given Schneck’s Chinese track record. Third, AI integration is likely to deepen; institutions evaluating radiology AI platforms can benefit from clearer alignment between Healthineers and software partners, in a context where capital flows into radiology AI<\/a> are forcing traditional vendors to accelerate differentiation. Fourth, regional markets should feel an indirect effect via launch schedules and equipment financing offers, especially during technology refresh cycles in public radiology.<\/p>\n Bundling four internal promotions indicates Bernd Montag is favoring cultural continuity over disruption \u2014 coherent for a company that has been delivering consistent revenue growth and expanding diagnostics margins. Group CFO Jochen Schmitz commented in a statement that "this transition from within our own ranks positions our management team for the future," while acknowledging colleagues who "over many years played a decisive role" in shaping what Siemens is today in imaging and cancer therapy.<\/p>\n Three signals deserve attention in the next quarters: pace of MR launches (especially low-field and dry-cool systems), commercial uptake of the Naeotom Alpha CT in mid-size hospitals and M&A activity in the software layer. The consolidation of leaders rooted in MR and CT suggests innovation will keep flowing through anchor modalities, alongside moves like the 10-year partnership with Onvida Health<\/a>, which bundles equipment with long-term managed services.<\/p>\nAdvanced therapies: Philipp Fischer takes over, Bertram steps into senior advisory<\/h2>\n
EMEA, China and global HR<\/h2>\n
Implications for radiology services<\/h2>\n
Signals to monitor in the next quarters<\/h2>\n